6855 — Ascentage Pharma International Income Statement
0.000.00%
Last trade - 00:00- HK$16.93bn
- HK$17.37bn
- CNY980.65m
Annual income statement for Ascentage Pharma International, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 12.4 | 27.9 | 210 | 222 | 981 |
| Cost of Revenue | |||||
| Gross Profit | 10.5 | 24.6 | 188 | 191 | 952 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 682 | 843 | 1,044 | 1,060 | 1,311 |
| Operating Profit | -669 | -816 | -834 | -838 | -331 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -675 | -832 | -887 | -933 | -395 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -678 | -782 | -883 | -926 | -406 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -678 | -782 | -883 | -926 | -405 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -678 | -782 | -883 | -926 | -405 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.14 | -3.07 | -3.35 | -3.28 | -1.34 |